US FDA declines to approve Regeneron's blood cancer therapy

Reuters · 03/25 11:07
US FDA declines to approve Regeneron's blood cancer therapy

- Regeneron Pharmaceuticals REGN.O said on Monday the U.S. Food and Drug Administration has declined to approve its blood cancer therapy for two most common subtypes of -Hodgkin lymphoma due to an issue related to the enrollment status of the confirmatory trials.


(Reporting by Sneha S K, Puyaan Singh and Sriparna Roy in Bengaluru; Editing by Shinjini Ganguli)

((Sneha.SK@thomsonreuters.com;))